Linked Life Data

2463980

Source:http://linkedlifedata.com/resource/pubmed/id/2463980

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2463980rdf:typepubmed:Citationlld:pubmed
pubmed-article:2463980lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:2463980lifeskim:mentionsumls-concept:C0152018lld:lifeskim
pubmed-article:2463980lifeskim:mentionsumls-concept:C0025677lld:lifeskim
pubmed-article:2463980lifeskim:mentionsumls-concept:C0030231lld:lifeskim
pubmed-article:2463980lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:2463980lifeskim:mentionsumls-concept:C0936233lld:lifeskim
pubmed-article:2463980lifeskim:mentionsumls-concept:C0205187lld:lifeskim
pubmed-article:2463980lifeskim:mentionsumls-concept:C0205088lld:lifeskim
pubmed-article:2463980pubmed:issue1lld:pubmed
pubmed-article:2463980pubmed:dateCreated1989-2-27lld:pubmed
pubmed-article:2463980pubmed:abstractTextBetween May 1976 and January 1982, 170 patients were entered in a randomized study comparing a combined treatment consisting of methotrexate followed by irradiation versus radiotherapy alone in patients with non metastatic inoperable oesophageal cancer. Methotrexate was administered subcutaneously in 4 days to a total dose of 24 mg/m2. Radiotherapy was performed, in both groups, at a dose of 56.25 Gy in 25 fractions (5 weeks). The administration of methotrexate did not lead to an increased intolerance to radiotherapy but severe hematological toxicities were observed in 7.8% of the cases. No difference in the duration of survival was detected. Initial performance status of the patients and their weight loss prior to entry on trial were the factors that were most predictive of the patient's prognosis.lld:pubmed
pubmed-article:2463980pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2463980pubmed:languageenglld:pubmed
pubmed-article:2463980pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2463980pubmed:citationSubsetIMlld:pubmed
pubmed-article:2463980pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2463980pubmed:statusMEDLINElld:pubmed
pubmed-article:2463980pubmed:monthJanlld:pubmed
pubmed-article:2463980pubmed:issn0360-3016lld:pubmed
pubmed-article:2463980pubmed:authorpubmed-author:NascaSSlld:pubmed
pubmed-article:2463980pubmed:authorpubmed-author:BleibergHHlld:pubmed
pubmed-article:2463980pubmed:authorpubmed-author:RousselAAlld:pubmed
pubmed-article:2463980pubmed:authorpubmed-author:PaillotBBlld:pubmed
pubmed-article:2463980pubmed:authorpubmed-author:GignouxMMlld:pubmed
pubmed-article:2463980pubmed:authorpubmed-author:HaegelePPlld:pubmed
pubmed-article:2463980pubmed:authorpubmed-author:JacobJ HJHlld:pubmed
pubmed-article:2463980pubmed:authorpubmed-author:DalesioOOlld:pubmed
pubmed-article:2463980pubmed:authorpubmed-author:JohlR GRGlld:pubmed
pubmed-article:2463980pubmed:authorpubmed-author:HeintzJ FJFlld:pubmed
pubmed-article:2463980pubmed:issnTypePrintlld:pubmed
pubmed-article:2463980pubmed:volume16lld:pubmed
pubmed-article:2463980pubmed:ownerNLMlld:pubmed
pubmed-article:2463980pubmed:authorsCompleteNlld:pubmed
pubmed-article:2463980pubmed:pagination67-72lld:pubmed
pubmed-article:2463980pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:meshHeadingpubmed-meshheading:2463980-...lld:pubmed
pubmed-article:2463980pubmed:year1989lld:pubmed
pubmed-article:2463980pubmed:articleTitlePalliative therapy of inoperable oesophageal carcinoma with radiotherapy and methotrexate: final results of a controlled clinical trial.lld:pubmed
pubmed-article:2463980pubmed:affiliationCentre Francois Baclesse, Caen, France.lld:pubmed
pubmed-article:2463980pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2463980pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2463980pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:2463980pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:2463980pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:2463980pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2463980lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2463980lld:pubmed